"How could anyone possibly see the manufacturing process of the longevity potion? The manufacturing process would never be leaked."
"The profit margin for life-extending drugs is enormous, and the potential for growth is also huge."
A very simple calculation method is to use the number of private banking clients disclosed by listed banks as the benchmark.
China Merchants Bank has 122,100 private banking clients, and ICBC has 199,500. In total, the eleven listed banks have more than one million private banking clients.
The minimum standard is that the working capital exceeds six million, which means that the potential customer base for the longevity drug is at least one million.
Of these one million people, very few are elderly or approaching old age, but they all have parents, and their partners all have parents.
The current life-extending drugs have an effect of extending life by 1-2 years, and we expect the price to be 50,000 yuan, which is completely affordable for these private banking clients.
With just one million employees, the revenue would be at least 50 billion.
The profits are huge, and the potential for growth is equally enormous.
It's a very simple principle: with the development of technology, the lifespan that life-extending drugs can extend will also increase.
From one to two years, it grew to five years, and then to ten years.
Meanwhile, subsequent research and development will definitely involve cooperation between Huaguo Pharmaceutical Group and foreign pharmaceutical giants, leaving other companies with no way to catch up.
Differentiated products, complete control over pricing, and an extremely deep competitive advantage.
There's simply no better business than this; it's even more appealing than Moutai.
The only thing to do now is to gamble—to gamble on which subsidiary Huaguo Pharmaceutical will place the production and sales of its longevity-enhancing drugs.
The guys on the stock forum were quick to calculate, offering various arguments about the huge market potential of life-extending drugs.
The research and development of longevity potions by China and the European Alliance lacked many magical elements.
However, during the production process, some materials still need to be processed using magic.
Therefore, production capacity will be lower than expected, and it is highly unlikely to meet the needs of millions of people in China.
Huaguo Pharmaceutical would never entrust all matters related to longevity drugs to its subsidiary listed companies.
The financial reports of the listed subsidiaries need to be disclosed to the public. If the production capacity and sales of longevity drugs do not match, it will raise a whole host of questions.
Huaguo Pharmaceutical plans to establish a separate subsidiary to be responsible for the production of the drug, and will sell any surplus production capacity to external parties.
Continue read on readnovelmtl.com
